What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs

On May 13, Voyager Therapeutics announced that it presented preclinical data for its Alzheimer’s disease gene therapy, VY1706 ...
Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...

Voyager Reports First Quarter 2026 Financial and Operating Results

VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 -- Multiple presentations at ...
Seeking Alpha

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering ...
AOL

Voyager 1 marks 48 years in space. Here's what to know about famous NASA mission

For nearly five decades, NASA's twin Voyager probes have plumbed the cosmos in search of answers to some of astronomy's most perplexing mysteries about our solar system and its place in the wider ...
Seeking Alpha

Voyager Provides Update on SOD1 ALS Gene Therapy Program

- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology ...